Author: cmyk

Life-cycle development Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)

Partnership AnaCardio receives patent grant in Europe for AC01

Partnership Knight Therapeutics and Helsinn Healthcare SA expand relationship and enter into exclusive license, distribution, and supply agreement for Onicit®

Partnership Helsinn Group and ESTEVE sign a partnership agreement renewal to commercialize AKYNZEO® and ALOXI® in Germany

Partnership Helsinn attends EORTC annual meeting 2024 with a focus on Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL)

News Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors

Corporate Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US

Life-cycle development Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland

Partnership Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic

Partnership Highlights of Helsinn’s attendance at ESMO 2023